Repeated low-level red light (RLRL) therapy is one of the most talked-about and most debated tools in childhood myopia control. The idea is simple: a child looks into a desktop device for three minutes, twice a day, while it shines a dim 650-nanometer red light onto the back of the eye. The randomized trial data showing slowed eye growth are genuinely strong, but the long-term safety picture is still unsettled, and almost everything we know comes from one country.
This page walks through how RLRL is supposed to work, what the actual clinical trials found, how it stacks up against atropine and other proven options, the safety signals that have eye doctors cautious, and who should and should not consider it. The treatment is not FDA cleared in the United States as of 2026, so context matters.
What RLRL Therapy Is
RLRL is short for "repeated low-level red light." It is not the same thing as the red light therapy panels people buy for skin or muscle recovery. Those panels shine red and near-infrared light on the body. RLRL is a small tabletop device the child looks directly into, aiming a low-power beam of pure red light through the pupil and onto the retina at the back of the eye.
The most-studied protocol is consistent across trials:
- Wavelength: 650 nanometers (visible deep red)
- Session length: 3 minutes
- Frequency: Twice a day, at least 4 hours apart
- Schedule: 5 days per week
- Power: About 0.29 milliwatts reaching the retina (with a 4-mm pupil)
- Supervision: Done at home, but the child should be monitored
The light source in commercial devices is a semiconductor laser diode, which is part of why safety questions keep coming up (more on that below). The treatment aims to slow how fast a child's eyeball lengthens. Myopia, or nearsightedness, happens largely because the eyeball grows too long from front to back. The longer the eye, the worse the nearsightedness and the higher the lifetime risk of serious problems like retinal detachment and myopic maculopathy.
How It Is Thought to Work
The honest answer is that nobody is fully certain. RLRL was discovered to slow myopia partly by accident, and the mechanism is still being worked out. A few theories have research support.
The choroid theory. The choroid is a layer of blood vessels behind the retina. In myopic eyes it tends to be thin. Red light appears to increase blood flow and thicken the choroid within days of starting treatment. A thicker choroid may push the retina forward slightly and signal the eye to stop elongating. Studies in both children and adults have measured choroidal thickening alongside a small shortening of the eye's axial length during RLRL.
The metabolism theory. Red light is absorbed by mitochondria, the energy factories inside cells, and can change how scleral and retinal tissue behaves. Some researchers think this slows the remodeling of the sclera (the white outer wall of the eye) that lets the eyeball stretch.
The dopamine and outdoor-light theory. Bright outdoor light is known to protect against myopia, possibly by boosting retinal dopamine. RLRL may be mimicking part of that protective light signal in a concentrated dose.
These are reasonable, biologically plausible ideas. But the gap between "the choroid thickens" and "the eye is permanently protected" is exactly where the long-term uncertainty lives.
One more nuance matters here. The choroidal thickening that RLRL produces shows up fast, within days, and it also disappears fast when treatment stops. That is a clue. If the benefit depends on a tissue change that reverses the moment you turn the device off, then the treatment may be propping up the eye rather than retraining it. That fits with the rebound data discussed later and is part of why some researchers describe RLRL as a "maintenance" therapy rather than a cure. A child is not fixing the eye; the child is holding it in place, day after day, for as long as the light keeps coming.
It also helps to understand why the dose is set the way it is. The 650-nm wavelength sits in the deep-red part of the visible spectrum, the band that penetrates ocular tissue well while staying below the energy levels that cause obvious heat damage. The power reaching the retina (around 0.29 milliwatts) is a small fraction of what a handheld laser pointer puts out. That low dose is the whole safety argument for RLRL. The catch is that "low power, many times, for years" is a different exposure profile than "low power, a few times," and the long-term arm of that equation has never been measured in a child.
The Actual Trial Evidence
This is where RLRL earns its attention. Several randomized controlled trials, the gold standard for medical evidence, have tested it. Here is the catch worth stating up front: nearly all of these trials were conducted in China, many share overlapping research groups, and follow-up rarely extends past two years. The short-term efficacy signal is real and consistent. The durability and safety over a childhood-long treatment course are not yet proven.
The landmark trial (Jiang 2022)
The most cited study is a multicenter RCT published in Ophthalmology in 2022. It enrolled children aged 8 to 13 with myopia between -1.00 and -5.00 diopters and compared RLRL plus glasses against glasses alone.
Over 12 months, the difference was large. The RLRL group's eyes grew 0.13 mm on average, while the control group's grew 0.38 mm, a difference of 0.26 mm. In refraction terms, the RLRL group worsened by only -0.20 D versus -0.79 D in controls. That is roughly a two-thirds reduction in progression, which is at the top end of anything in the myopia field.
Premyopia prevention (He 2023)
A JAMA Network Open trial tested whether RLRL could stop myopia before it starts in "premyopic" children (slightly nearsighted but not yet meeting the threshold). Over 12 months, fewer children in the RLRL group crossed into true myopia compared to controls. It is one of the few prevention signals in the whole field, though prevention claims need replication outside China.
High myopia (Multiple 2024 trials)
Two 2024 trials looked at children who already had high myopia (-6.00 D or worse), the group at highest lifetime risk. RLRL again slowed and sometimes even reversed axial growth over 12 months, with a meaningful share of children showing measurable eye shortening. High myopia is where slowing progression matters most, so these results drew attention.
Combined with other treatments
A 2024 multicenter RCT in Ophthalmology tested RLRL on top of orthokeratology (overnight rigid contact lenses). The combination slowed axial growth more than ortho-k alone, suggesting RLRL can stack with existing tools rather than replace them.
The rebound problem (Xiong 2022)
Here is the finding that gets glossed over in marketing. A 2-year post-trial follow-up showed that when children stopped RLRL, their eyes did not just resume a normal growth rate. They sped up. This "rebound" meant some of the early gains were partly clawed back, and the bigger the initial effect, the bigger the rebound tended to be. The practical message: RLRL may not be a short course you finish. It may be something a child has to keep doing for years, which raises the stakes on long-term safety.
Evidence summary table
| Study (first author, year) | Design | Population | Key 12-month finding | Honest caveat |
|---|---|---|---|---|
| Jiang 2022 (Ophthalmology) | Multicenter RCT, 246 analyzed | Ages 8-13, -1 to -5 D | Axial growth 0.13 vs 0.38 mm; SER -0.20 vs -0.79 D | Single-blind; China only |
| He 2023 (JAMA Netw Open) | School-based RCT | Premyopic children | Lower rate of converting to myopia | Prevention signal needs replication |
| 2024 high-myopia RCTs | Multicenter RCTs | Children with ≥ -6 D | Slowed and sometimes reversed axial growth | Short follow-up; high-risk group |
| RLRL + ortho-k 2024 (Ophthalmology) | Multicenter RCT | Myopic children on ortho-k | Added benefit over ortho-k alone | Combination, not standalone proof |
| Xiong 2022 (Clin Exp Ophthalmol) | 2-year follow-up | Former trial participants | Rebound acceleration after stopping | Suggests open-ended treatment |
How RLRL Compares to Proven Options
RLRL is not the only myopia-control tool, and it is the newest and least proven of the bunch when it comes to long-term safety. The established options have years more real-world use behind them.
| Treatment | How it works | Roughly how much it slows progression | Track record | Main downside |
|---|---|---|---|---|
| Low-dose atropine (0.01-0.05%) | Eye drops, mechanism not fully known | Modest to moderate; 0.05% is stronger | Years of data, multiple countries | Light sensitivity, rebound at higher doses |
| Orthokeratology (ortho-k) | Overnight rigid lenses reshape cornea | Moderate to strong | Long track record | Small risk of corneal infection |
| Soft myopia-control contacts (e.g., MiSight) | Daytime dual-focus soft lenses | Moderate | FDA cleared in the US | Contact lens hygiene needed |
| Myopia-control glasses (DIMS/HAL lenses) | Special peripheral-defocus lens design | Moderate | Growing data | Less effect than ortho-k or atropine |
| RLRL therapy | Daily low-power red light to retina | Strong in short-term trials | New; mostly 1-2 year China data | Not FDA cleared; safety signals; rebound |
The short-term efficacy of RLRL looks as good as or better than these on paper. What it lacks is the years of safety reassurance the others have, plus regulatory clearance in the US. Many pediatric eye specialists outside Asia treat it as promising but not yet ready for routine recommendation.
A fair comparison also has to weigh effort and risk, not just effect size. Low-dose atropine is one drop at bedtime and decades of ophthalmology experience back the general safety of atropine at these tiny concentrations. Ortho-k and soft myopia-control lenses carry a small but real infection risk that good lens hygiene keeps low, and that risk is well characterized. RLRL flips the trade: the daily effort is modest (six minutes total), but the long-term risk profile is the least understood of any option on the table. A parent choosing between these is really choosing between a known small risk and an unknown one. For a low-risk child with slowly progressing myopia, most clinicians would reach for the established tools first. For a child with aggressive, high myopia where the lifetime stakes are higher, the calculus shifts and RLRL becomes more tempting, which is exactly why the high-myopia trials drew so much interest.
If you want the broader picture on how light wavelengths are used clinically, our red light vs near-infrared explainer covers why the specific wavelength matters, and our photobiomodulation science guide explains the cellular mechanisms researchers are debating.
The Safety Picture: Honest and Mixed
This is the part that deserves the most care, because a child's vision is at stake and the marketing tends to skip past it.
What the trials reported
Across the published RCTs, the safety record looked reassuring on the surface. No severe adverse events, no functional vision loss, and no structural damage on OCT scans were reported in the main efficacy trials. The most common complaint was a temporary afterimage (a faint glow lingering after a session), which usually faded within about six minutes.
A 2024 systematic review pulled together 20 studies covering roughly 2,380 children. It found a low rate of side effects and concluded that no irreversible vision loss or eye structural damage had been identified. That sounds clean.
Why "clean so far" is not the same as "safe"
Read the same review more carefully and the caution appears. The median treatment duration in those studies was only about 9 months, and the longest ran 24 months. Myopia management in a child can last a decade. We simply do not have data on what daily retinal light exposure does over five or ten years.
The review's authors did not declare RLRL safe and move on. They called for adequately powered studies of longer duration and recommended active monitoring with fundus photos, OCT imaging, home visual acuity checks, and tracking how long afterimages last.
The warning signals
Two specific findings keep experts cautious:
Case reports of retinal injury. At least one child developed a decline in vision with OCT abnormalities (disruption of the photoreceptor layers in the central retina) after months of RLRL. The encouraging part: the damage reversed completely about four months after stopping treatment. The sobering part: it happened at all, and it looked similar to the macular damage caused by laser-pointer injuries.
Reduced cone density. A 2025 study in JAMA Ophthalmology compared children who had used RLRL for over a year against non-users. The RLRL users showed lower cone photoreceptor density near the center of the retina, and some had abnormal drusen-like deposits. Whether this is harmless or an early sign of cumulative damage is unknown, and that uncertainty is exactly the problem.
On top of that, lab testing has found that some commercial RLRL devices can exceed accepted laser safety limits, meaning device quality and oversight are not uniform. Because the light source is a laser diode rather than an LED, a poorly calibrated or counterfeit unit could deliver more energy to the retina than the studied protocol ever intended. That is a different kind of risk than the treatment itself, and it argues strongly against buying an unverified device online.
How should a family think about these conflicting safety signals? One useful frame: the trials measured the average child over months, while the worrying findings (the injury case report, the cone-density change) are about what happens at the edges and over the long run. Both can be true at once. RLRL can be low-risk for most children over a year and still carry a small chance of a problem that only shows up in some children, or only after years of use. Averages reassure; tails are where the unanswered questions sit. Until longer and larger studies close that gap, treating RLRL as experimental rather than routine is the conservative and defensible position.
Who should not use it
- Children with a history of light sensitivity disorders or retinal disease
- Any child who has a prolonged afterimage (lasting more than about five minutes) after sessions, which is treated as a reason to stop
- Families who cannot commit to regular eye exams with OCT monitoring
- Anyone expecting a finish line, given the rebound data
For a fuller look at when light-based therapies are not appropriate, see our guide on red light therapy contraindications and the dedicated eye safety and goggles guide.
Regulatory Status in 2026
As of 2026, RLRL devices for myopia are not cleared by the US Food and Drug Administration. They are used in China and Australia and a handful of other markets, but a US family cannot get an FDA-cleared RLRL device through normal channels. This is a meaningful difference from soft myopia-control contact lenses, which do have US clearance.
That regulatory gap is not a technicality. It means the device class has not cleared the bar US regulators set for marketed medical devices, and it reflects the unsettled long-term safety questions rather than a lack of interest. Families researching RLRL should treat any US seller making myopia claims with skepticism.
Who RLRL Might Be For
Setting aside the open questions, RLRL is most relevant to a specific child:
- A child with progressing myopia, especially fast-progressing or already-high myopia, where the lifetime risk of eye disease is real
- A family with access to a pediatric ophthalmologist who can do baseline and follow-up OCT monitoring
- Situations where established options (atropine, ortho-k, myopia-control lenses) have not worked well or are not tolerated
- A family that understands this is likely a multi-year commitment, not a quick fix, and accepts the unknowns
It is not a casual wellness purchase. It is a retinal light exposure that a child does twice a day for years, and it should be supervised by an eye doctor, not bought online and used unmonitored.
The Bottom Line
RLRL therapy has some of the strongest short-term efficacy data in the entire myopia-control field. The randomized trials are real, the effect sizes are large, and the slowing of eye growth is consistent. That is not hype.
But three things keep it from being a clear recommendation: the evidence is almost entirely short-term and from one country, stopping treatment can trigger rebound that erases gains, and there are early safety signals (case reports of reversible retinal injury and reduced cone density) that nobody can yet explain away. It is not FDA cleared in the US. The most honest summary is that RLRL is promising, watched closely, and not yet proven safe for the long haul. Any decision belongs with a pediatric eye specialist, not a marketing page.
Frequently Asked Questions
Is RLRL therapy FDA approved for children?
No. As of 2026, RLRL devices for myopia control are not cleared by the FDA in the United States. They are used in China, Australia, and some other countries, but US families cannot obtain an FDA-cleared RLRL myopia device through normal medical channels.
How well does RLRL actually slow myopia in trials?
In the landmark 12-month RCT, children using RLRL had axial eye growth of 0.13 mm versus 0.38 mm in the control group, roughly a two-thirds reduction in progression. That is among the strongest short-term effects in the myopia field, but follow-up beyond two years is limited.
Is RLRL safe for a child's eyes?
The published trials reported no irreversible damage, and the most common side effect was a brief afterimage. But there are real cautions: at least one reversible retinal injury case report, a 2025 study showing reduced cone density in long-term users, and a lack of data beyond about two years. It should only be done under eye-doctor supervision with OCT monitoring.
What happens if my child stops RLRL therapy?
Research shows a rebound effect. When children stopped treatment, their eyes grew faster than normal for a period, clawing back some of the early benefit. This suggests RLRL may need to continue for years rather than be used as a short course, which raises the importance of long-term safety data.
Is RLRL the same as red light therapy panels for skin?
No. Skin and recovery panels shine red and near-infrared light on the body from a distance. RLRL is a small device a child looks directly into, aiming a low-power 650-nm beam through the pupil onto the retina. The targets, doses, and safety considerations are completely different.
Medical disclaimer: This article is for general information only and is not medical advice. Myopia management decisions for a child should be made with a qualified pediatric ophthalmologist or optometrist. Do not start or stop any treatment based on this page alone.
Citations
- Effect of Repeated Low-Level Red-Light Therapy for Myopia Control in Children: A Multicenter Randomized Controlled Trial (Jiang et al., Ophthalmology 2022, PMID 34863776)
- Effect of Repeated Low-level Red Light on Myopia Prevention Among Children in China With Premyopia: A Randomized Clinical Trial (He et al., JAMA Network Open 2023, PMID 37099298)
- Repeated Low-Level Red Light Therapy for Myopia Control in High Myopia Children and Adolescents: A Randomized Clinical Trial (Ophthalmology 2024, PMID 38849054)
- Myopia Control Effect of Repeated Low-Level Red-Light Therapy Combined with Orthokeratology: A Multicenter Randomized Controlled Trial (Ophthalmology 2024, PMID 38763303)
- Sustained and rebound effect of repeated low-level red-light therapy on myopia control: A 2-year post-trial follow-up study (Xiong et al., Clin Exp Ophthalmol 2022, PMID 36054314)
- Safety of repeated low-level red-light therapy for myopia: A systematic review (Asia Pac J Ophthalmol 2024, PMID 39672511)
- Cone Density Changes After Repeated Low-Level Red Light Treatment in Children With Myopia (JAMA Ophthalmology 2025, PMID 40272813)
- PubMed: repeated low-level red-light therapy myopia children randomized trials (search)
- American Academy of Ophthalmology: Myopia treatment overview